BioCryst Pharmaceuticals Ownership | Who Owns BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals Ownership Summary
BioCryst Pharmaceuticals is owned by 16.35% institutional investors, 1.32% insiders, and 82.32% retail investors. Vanguard group is the largest institutional shareholder, holding 10.60% of BCRX shares. BioPharma Credit Ord is the top mutual fund, with 8.23% of its assets in BioCryst Pharmaceuticals shares.
BCRX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | BioCryst Pharmaceuticals | 16.35% | 1.32% | 82.32% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 22.27M | 10.60% | $173.73M |
| Blackrock funding, inc. /de | 21.14M | 10.06% | $164.87M |
| Blackrock | 19.96M | 9.68% | $123.33M |
| Deerfield management company, l.p. (series c) | 12.17M | 5.82% | $92.36M |
| State street | 9.81M | 4.69% | $74.44M |
| Kynam capital management, lp | 9.39M | 4.49% | $71.27M |
| Alkeon capital management | 5.46M | 2.61% | $41.47M |
| Ubs group | 5.26M | 2.50% | $41.06M |
| Arrowstreet capital, limited partnership | 5.23M | 2.50% | $39.67M |
| Geode capital management | 5.05M | 2.40% | $39.43M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rp management | 3.85M | 12.84% | $29.23M |
| Kynam capital management, lp | 9.39M | 5.31% | $71.27M |
| Deerfield management company, l.p. (series c) | 12.17M | 1.41% | $92.36M |
| Parkman healthcare partners | 1.01M | 0.80% | $7.69M |
| Rice hall james & associates | 1.88M | 0.78% | $14.27M |
| Rock springs capital management lp | 2.68M | 0.77% | $20.14M |
| Eversept partners, lp | 1.37M | 0.72% | $10.43M |
| Qtr family wealth | 157.14K | 0.57% | $1.19M |
| Doliver advisors, lp | 274.33K | 0.54% | $2.14M |
| Hussman strategic advisors | 252.00K | 0.48% | $1.97M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deerfield management company, l.p. (series c) | 12.17M | 1.41% | 7.48M |
| Hood river capital management | 3.62M | 0.32% | 2.38M |
| Blackrock | 19.96M | 0.00% | 1.52M |
| Nantahala capital management | 1.36M | 0.35% | 1.36M |
| State street | 9.81M | 0.00% | 1.30M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Morgan stanley | 1.75M | 0.00% | -3.46M |
| Braidwell lp | - | - | -3.38M |
| Avoro capital advisors | 1.25M | 0.12% | -3.25M |
| Assenagon asset management | 359.58K | 0.00% | -2.73M |
| Walleye capital | 227.06K | 0.01% | -2.07M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Nantahala capital management | 1.36M | 0.35% | 1.36M | $10.58M |
| Cubist systematic strategies | 1.25M | 0.05% | 1.25M | $9.46M |
| Dimensional fund advisors lp | 1.23M | 0.00% | 1.23M | $9.59M |
| Abrdn | 913.59K | 0.01% | 913.59K | $7.13M |
| Orbimed advisors | 901.50K | 0.16% | 901.50K | $6.84M |
Sold Out
| Holder | Change |
|---|---|
| Tfo-tdc | -3.00 |
| Financial gravity asset management | -8.00 |
| Newedge advisors | -11.00 |
| Dinuzzo private wealth | -13.00 |
| Newbridge financial services group | -15.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 79 | -73.04% | 34,367,278 | -82.30% | 16 | 0.19% | 37 | -72.79% | 25 | -75.49% |
| Sep 30, 2025 | 101 | -65.88% | 38,849,402 | -78.37% | 18 | 0.25% | 42 | -73.58% | 35 | -57.83% |
| Jun 30, 2025 | 304 | 9.35% | 196,946,754 | 15.72% | 94 | 1.42% | 161 | 5.92% | 86 | 30.30% |
| Mar 31, 2025 | 277 | 2.59% | 174,118,175 | 3.86% | 83 | 1.27% | 150 | 29.31% | 66 | -25.00% |
| Dec 31, 2024 | 265 | -1.49% | 167,630,080 | -2.81% | 81 | 1.17% | 114 | -14.29% | 87 | 17.57% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BioPharma Credit Ord | 17.22M | 8.23% | 17.22M |
| Vanguard US Total Market Shares ETF | 6.57M | 3.14% | -18.55K |
| Vanguard Total Stock Mkt Idx Inv | 7.30M | 2.92% | -152.50K |
| State Street® SPDR® S&P® Biotech ETF | 6.56M | 2.62% | -35.31K |
| iShares Russell 2000 ETF | 5.67M | 2.26% | 1.69M |
| SPDR® S&P Biotech ETF | 3.67M | 1.75% | 8.19K |
| ACAP Strategic A | 2.70M | 1.08% | -121.24K |
| Vanguard Small Cap Index | 2.63M | 1.05% | 233.72K |
| Vanguard Strategic Equity Inv | 2.57M | 1.03% | 634.66K |
| Vanguard Institutional Extnd Mkt Idx Tr | 2.57M | 1.03% | 8.42K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 22, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $166.56K |
| Dec 15, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $162.26K |
| Dec 01, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $646.51K |
| Dec 02, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $367.22K |
| Dec 03, 2025 | Barnes Alane P | Chief Legal Officer | Sell | $151.24K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | - |
| 2026 Q1 | - | - |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
BCRX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools